The University of Nevada, Reno School of Medicine

The IL-13 Story in Atopic Dermatitis: Characterizing Pathways and Therapeutic Performance

DO, MS, FAAD

Examine the pathophysiological pathways of atopic dermatitis (AD) and the impact of interleukin (IL)-13 on disease severity and chronicity 

Utilize the latest clinical data to differentiate available biologic IL-13 therapies and guide therapy selection 

Evaluate the safety and efficacy of emerging IL-13 therapies to support timely integration into clinical practice 

large_Concept02.png

medium_Concept02.png

small_Concept02.png

thumbnail_Concept02.png

Concept02.png

Atopic dermatitis (AD) is a chronic, relapsing inflammatory dermatosis characterized by epidermal barrier dysfunction, type 2–skewed immune activation, and intense pruritus with eczematous lesions. Disease expression varies by age and severity, with recurrent flares and a well-established association with atopic comorbidities including asthma, allergic rhinitis, and food allergy.

This hub gathers the evidence, expert perspective, and practical insight shaping how atopic dermatitis is understood and treated today, connecting emerging therapies with the everyday decisions that define long-term care.

WCH26: The IL-13 Story in Atopic Dermatitis: Characterizing Pathways and Therapeutic Performance

About

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures

WCH26: ​​The IL-13 Story in Atopic Dermatitis: Characterizing Pathways and Therapeutic Performance

About

About

Learning Objectives

Learning Objectives

Intended Audience

Intended Audience

Faculty

Faculty

Accreditation Statement

Accreditation Statement

Credit Designation Statement

Credit Designation Statement

Disclosures

Disclosures

WCH26: The IL-13 Story in Atopic Dermatitis: Characterizing Pathways and Therapeutic Performance